Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.58 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.58 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.58 |
| ▸ | CPB2 | Q96IY4 | 9/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.51 |
| ▸ | GSR | P00390 | 1/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1711264 | 1.00 | ERAP2 (0.58) | ERAP2ERAP1LNPEPCPB2FOLH1 | |
| SCHEMBL29714923 | 1.00 | ERAP2 (0.58) | ERAP2ERAP1LNPEPCPB2FOLH1 | |
| SCHEMBL29496718 | 1.00 | ERAP2 (0.58) | ERAP2ERAP1LNPEPCPB2FOLH1 | |
| SCHEMBL29456901 | 1.00 | ERAP2 (0.58) | ERAP2ERAP1LNPEPCPB2FOLH1 | |
| SCHEMBL10928123 | 1.00 | ERAP2 (0.58) | ERAP2ERAP1LNPEPCPB2FOLH1 | |
| SCHEMBL29898192 | 0.97 | ERAP2 (0.56) | ERAP2ERAP1LNPEPCPB2FOLH1 | |
| SCHEMBL29714947 | 0.96 | ERAP2 (0.55) | ERAP2ERAP1LNPEPCPB2FOLH1 | |
| SCHEMBL30785147 | 0.96 | ERAP2 (0.55) | ERAP2ERAP1LNPEPCPB2FOLH1 | |
| SCHEMBL29543277 | 0.95 | ERAP2 (0.54) | ERAP2ERAP1LNPEPCPB2FOLH1 | |
| SCHEMBL31287939 | 0.95 | ERAP2 (0.54) | ERAP2ERAP1LNPEPCPB2FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4684807-A1 | LINKER AND USE THEREOF IN LIGAND DRUG CONJUGATE | Duality Biologics (Shanghai) Co., Ltd. (CN) | 2026-01-28 | — | — | EP | claimed |
| US-12458680-B2 | Reconstitutable teverelix-TFA composition | ANTEV LIMITED (GB) | 2025-11-04 | — | — | US | claimed |
| EP-4612124-A1 | AZOTOMYCIN PRODRUGS WITH PREFERENTIAL TUMOR DELIVERY | The Johns Hopkins University (US) | 2025-09-10 | — | — | EP | claimed |
| CN-119300868-A | Camptothecins compound and conjugate thereof, preparation method and application thereof | 映恩生物科技(上海)有限公司 | 2025-01-10 | — | — | CN | claimed |
| CN-119053607-A | Camptothecins compound and conjugate thereof, preparation method and application thereof | 映恩生物科技(上海)有限公司 | 2024-11-29 | — | — | CN | claimed |
| WO-2024193692-A1 | LINKER AND USE THEREOF IN LIGAND DRUG CONJUGATE | 映恩生物制药（苏州）有限公司 | 2024-09-26 | — | — | WO | claimed |
| CN-118684724-A | Linker and use thereof in ligand drug conjugates | 映恩生物制药（苏州）有限公司 | 2024-09-24 | — | — | CN | claimed |
| CN-118681035-A | Ligand drug conjugate and preparation method and application thereof | 映恩生物制药（苏州）有限公司 | 2024-09-24 | — | — | CN | claimed |
| CN-118161591-A | Tiveric-TFA compositions | 安迪威有限公司 | 2024-06-11 | — | — | CN | claimed |
| WO-2024097320-A1 | AZOTOMYCIN PRODRUGS WITH PREFERENTIAL TUMOR DELIVERY | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-05-10 | — | — | WO | claimed |
| CN-117015381-A | Novel steroid payloads, steroid linkers, ADCs containing the same and uses thereof | 伊穆奈克斯特股份有限公司 | 2023-11-07 | — | — | CN | claimed |
| WO-2023212662-A2 | COMPOSITIONS AND METHODS FOR MODULATING ANTIGEN BINDING ACTIVITY | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2023-11-02 | — | — | WO | claimed |
| WO-2023120405-A1 | COMPOSITION FOR MINIMIZING PRODUCTION AND/OR ACCUMULATION OF AMYLOID β | サントリーホールディングス株式会社 | 2023-06-29 | — | — | WO | claimed |
| EP-4011373-A1 | TEVERELIX-TFA COMPOSITION | Antev Limited (GB) | 2022-06-15 | — | — | EP | claimed |
| US-20220177521-A1 | PROCESS FOR THE PREPARATION OF DEGARELIX | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-06-09 | — | — | US | claimed |
| CN-110294800-B | Preparation method of somaglutide | 齐鲁制药有限公司 | 2022-03-04 | — | — | CN | claimed |
| EP-3958910-A1 | ANTI-CD45 ANTIBODY DRUG CONJUGATES AND USES THEREOF | Magenta Therapeutics, Inc. (US) | 2022-03-02 | — | — | EP | claimed |
| WO-2022034882-A1 | CORONAVIRUS PROPAGATION METHOD | 花王株式会社 | 2022-02-17 | — | — | WO | claimed |
| CN-100522249-C | Elongated multiple spacers in activatable prodrugs | SINTAGAR B V (NL) | 2009-08-05 | — | — | CN | claimed |
| CN-1511044-A | Elogated and multiple spacers in activatible prodrugs | — | 2004-07-07 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177521-A1 | PROCESS FOR THE PREPARATION OF DEGARELIX | VIP, PEPD, SSTR4 | ERAP2 1889/4885ERAP1 959/4885LNPEP 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.